Generex Biotechnology Corp. Announces Publication of Oral-Lyn Research Paper

Strategic Insights -

Diabetes researchers from Hadassah-Hebrew University Hospital in Jerusalem, Israel, along with Generex consultant Dr. Pankaj Modi, have published a research paper on Oral-Lyn, a buccal insulin spray. The study, published in the December 2004 edition of Clinical Therapeutics, compared the pharmacokinetic and pharmacodynamic properties of Oral-Lyn and subcutaneous insulin in healthy male subjects. The results showed that Oral-Lyn had a higher Cmax, shorter Tmax, and faster time to peak glucose uptake compared to subcutaneous insulin.

Key Takeaways:

  • The study, published in Clinical Therapeutics, compared the pharmacokinetic and pharmacodynamic properties of Oral-Lyn and subcutaneous insulin in healthy male subjects.
  • Oral-Lyn was associated with a higher Cmax, shorter Tmax, and faster time to peak glucose uptake compared to subcutaneous insulin.
  • The short Tmax and 120-minute duration of effect of Oral-Lyn suggest that it may be a promising alternative for fulfilling meal-related insulin requirements in persons with diabetes.
  • The study was conducted by researchers from Hadassah-Hebrew University Hospital in Jerusalem, Israel, and Generex consultant Dr. Pankaj Modi.
  • Generex is engaged in the research and development of drug-delivery systems and technology.

Statistics:

  • The study was conducted in a small, selected population of healthy male subjects (number not specified).
  • Oral-Lyn had a higher Cmax compared to subcutaneous insulin (exact values not specified).
  • Oral-Lyn had a shorter Tmax compared to subcutaneous insulin (exact values not specified).
  • The 120-minute duration of effect of Oral-Lyn suggests that it may be suitable for meal-related insulin requirements.
  • The study was published in the December 2004 edition of Clinical Therapeutics.

Sources:

  • Generex Biotechnology Corp., GNBT
  • Dr. Itamar Raz, Dr. Simona Cernea, Dr. Miriam Kidron, and Dr. Jay Wohlgelernter, Hadassah-Hebrew University Hospital
  • Dr. Pankaj Modi, Generex consultant
  • Clinical Therapeutics, December 2004 edition
  • Health & Medicine Week editors, Health & Medicine Week via NewsRx.com & NewsRx.net.